CRIB: Heterodimeric Fc platform
-
Full mAb scaffold with
tuned interaction to generate multi-fuctional Abs or fusion proteins with improved efficacy
-
Maintain Fc functions: Full ADCC/CDC activity; Non compromised in
vivo half-life
-
Validated in application of anti-HER2 bispecific mAb （currently spin off to Jiangsu Alphamab) and mAb-cytokine
fusions
-
PCT filed
